Summary:
- Moderna announced updates on its pandemic influenza vaccine program, including positive results from a Phase 1 study of its mRNA-based H7N9 influenza vaccine candidate.
- The vaccine candidate was found to be generally well-tolerated and induced robust immune responses in healthy adults, paving the way for further clinical development.
- Moderna also shared plans to advance its pandemic influenza vaccine strategy, including the development of a universal flu vaccine and the potential to combine its influenza and COVID-19 vaccine candidates into a single shot.